5-Methoxy-thiophen-2-carbonsaeure-chlorid | 42457-22-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 5-Methoxy-thiophen-2-carbonsaeure-chlorid
• 英文别名: 5-methoxythiophene-2-carbonyl chloride；5-methoxy-2-thiophenecarbonyl chloride；5-methoxy thenoyl chloride
• CAS: 42457-22-7
• 化学式: C₆H₅ClO₂S
• 分子量: 176.624
• InChiKey: XKLIPCLUPXEHPE-UHFFFAOYSA-N

物化性质

• 沸点：
  70-75 °C(Press: 0.03 Torr)
• 密度：
  1.365±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  54.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-Methoxy-thiophen-2-carbonsaeure-chlorid 在 三乙胺 作用下， 以 二氯甲烷 、 水 、 二甲基亚砜 为溶剂， 生成
  参考文献：
  名称：

  4-硝基苯基 2-噻吩羧酸盐与 R2NH/R2NH2+在 20 mol % DMSO（水溶液）中的反应。5-噻吩基取代基和碱基强度的影响

  摘要：

  值随着吸电子 5-噻吩基取代基的增加而增加，Hammett 图是线性的，除了 X = MeO，Yukawa-Tsuno 图是线性的，ρ = 0.79-1.32 和 r = 0.28-0.93，分别。随着亲核试剂的增强，ρ值增加，r值降低，表明C=O键处的电子密度增加，共振需求减少。这些结果被解释为随着反应性的增加，过渡态的 NC 键形成增强。关键词：氨解、Bronsted 型图、Hammett 图、Yukawa-Tsuno 图

  DOI：

  10.5012/bkcs.2013.34.7.2036
• 作为产物：
  描述：

  5-甲氧基-2-噻吩甲酸 以87的产率得到5-Methoxy-thiophen-2-carbonsaeure-chlorid
  参考文献：
  名称：

  Thienyloxyalkylamine derivatives, process for their preparation and

  摘要：

  通式为：##STR1##的Thienyloxyalkylamine衍生物，其中--O--CH.sub.2 --CH.sub.2 --NR.sub.2 R.sub.3位于噻吩环的4或5位; R.sub.1为氢、卤素、CF.sub.3、烷基或烷氧基; R.sub.2和R.sub.3相同或不同，分别为烷基、环烷基、烯基或炔基，每个原子有多达8个碳，或NR.sub.2 R.sub.3是一个5到7个成员的饱和杂环环，可选地含有进一步的杂原子，其为氧或氮，可选地由具有1到3个碳原子的烷基基团取代; n是1到5的整数;以及它们的酸加成盐，适用于治疗心律失常。

  公开号：

  US05100911A1

文献信息

• Reactions of 2,4‐Dinitrophenyl 5‐substituted‐2‐thiophenecarboxylates with R ₂ NH/R ₂ NH ₂ ⁺ in 20 Mol % DMSO(aq). Effects of 5‐Thienyl Substituent and Leaving Group on the Reaction Mechanism
  作者：Sang Yong Pyun、Kyu Cheol Paik、Man So Han、Bong Rae Cho

  DOI：10.1002/bkcs.11857

  日期：2019.10

  Reactions of 2,4‐dinitrophenyl 2‐thiophenecarboxylate (2a–d) with R2NH/R2NH2+ in 20 mol % DMSO(aq) have been studied. The reactions are overall second order, first order to the substrates, and first order to the nucleophiles. The Brönsted plots showed downward curves with pKa0 = 9.5, β1 = 0.22–0.34, and β2 = 0.85–0.92. The k1 values increased with a stronger electron‐withdrawing 5‐thienyl substituent

  研究了2,4-二硝基苯基2-噻吩羧酸酯（2a–d）与R 2 NH / R 2 NH 2 +在20 mol％DMSO（水溶液）中的反应。反应总体上是二级的，对底物的一级，对亲核试剂的一级。该布朗斯台德曲线表明与对向下曲线ķ一个0 = 9.5，β 1 = 0.22-0.34，和β 2 = 0.85-0.92。所述ķ 1值具有更强的吸电子-5-噻吩基取代基和亲核试剂更强增加，而ķ 2 / ķ -1所有5-噻吩基取代基的值几乎相同。5-噻吩基取代基对反应速率的影响在Yukawa-Tsuno图上显示出极好的相关性，其中ρ= 1.28–2.16和r = 0.20–0.60。亲核力越强，ρ值越大，r值越小，这表明羰基碳的电子密度增加，共振需求降低。根据这些结果，提出了一种速率确定步骤有所变化的逐步机制。
• Photochromic naphtho [2,1-b]pyran compounds containing bithienyl or terthienyl substituents, process for their manufacture, and photochromic materials and articles obtained
  申请人：Essilor International Compagnie Generale d'Optique

  公开号：US06312811B1

  公开（公告）日：2001-11-06

  The photochromic compounds of the invention correspond to the formula: in which Th2 represents a bithienyl group in one of the positions 5 to 10 of the naphthenic ring system system, R1 denotes a bithienyl or trithienyl group and R2 denotes a bithienyl, trithienyl, aryl, naphthyl, thienyl, furyl, pyrrolyl or N-alkylpyrrolyl group.

  该发明的光致变色化合物对应于以下结构式：其中Th2代表萘环系统中5到10位置的二噻吩基团，R1表示二噻吩或三噻吩基团，R2表示二噻吩、三噻吩、芳基、萘基、噻吩基、呋喃基、吡咯基或N-烷基吡咯基团。
• 3-substituted-2-oxindole derivatives as antiinflammatory agents
  申请人：PFIZER INC.

  公开号：EP0393936A1

  公开（公告）日：1990-10-24

  This invention relates to novel 3-substituted-2-oxindole derivatives which are inhibitors of prostaglandin H2 synthase, 5-lipoxygenase and interleukin-1 biosynthesis. The compounds of the invention are useful as inhibitors of prostaglandin H2 synthase and interleukin-1 biosynthesis, per se, and as analgesic, antiinflammatory and antiarthritic agents in the treatment of chronic inflammatory diseases. This invention also relates to pharmaceutical compositions comprising said 3-substituted-2-oxindole derivatives; to methods of inhibiting prostaglandin H2 synthase and biosynthesis of interleukin-1; and to treating chronic inflammatory diseases in a mammal with said compounds. Further, this invention relates to certain novel carboxylic acids useful as intermediates in the preparation of the 3-substituted-2-oxindole derivatives of this invention and to a process for the preparation of the 3-substituted-2-oxindole derivatives.

  本发明涉及新型 3-取代-2-氧化吲哚衍生物，它们是前列腺素 H2 合酶、5-脂氧合酶和白细胞介素-1 生物合成的抑制剂。本发明的化合物本身可用作前列腺素 H2 合酶和白细胞介素-1 生物合成的抑制剂，也可用作治疗慢性炎症性疾病的镇痛、抗炎和抗关节炎药物。本发明还涉及包含所述 3-取代-2-氧化吲哚衍生物的药物组合物；涉及抑制前列腺素 H2 合酶和白细胞介素-1 生物合成的方法；涉及用所述化合物治疗哺乳动物的慢性炎症疾病。此外，本发明还涉及某些可用作制备本发明 3-取代-2-吲哚衍生物中间体的新型羧酸，以及制备 3-取代-2-吲哚衍生物的工艺。
• ——
  作者：

  DOI：——

  日期：——
• Discovery of <i>N</i>-[2-Hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (Darexaban, YM150) as a Potent and Orally Available Factor Xa Inhibitor
  作者：Fukushi Hirayama、Hiroyuki Koshio、Tsukasa Ishihara、Shunichiro Hachiya、Keizo Sugasawa、Yuji Koga、Norio Seki、Ryouta Shiraki、Takeshi Shigenaga、Yoshiyuki Iwatsuki、Yumiko Moritani、Kenichi Mori、Takeshi Kadokura、Tomihisa Kawasaki、Yuzo Matsumoto、Shuichi Sakamoto、Shin-ichi Tsukamoto

  DOI：10.1021/jm200868m

  日期：2011.12.8

  Inhibitors of factor Xa (FXa), a crucial serine protease in the coagulation cascade, have attracted a great deal of attention as a target for developing antithrombotic agents. We previously reported findings from our optimization study of a high-throughput screening (HTS) derived lead compound la that resulted in the discovery of potent amidine-containing FXa inhibitors represented by compound 2. We also conducted an alternative optimization study of la without incorporating a strong basic amidine group, which generally has an adverse effect on the pharmacokinetic profile after oral administration. Replacement of 4-methoxybenzene with a 1,4-benzodiazepine structure and introduction of a hydroxy group at the central benzene led to the discovery of the potent and orally effective factor Xa inhibitor 14i (darexaban, YM150). Subsequent extensive study revealed a unique aspect to the pharmacokinetic profile of this compound, wherein the hydroxy moiety of 141 is rapidly transformed into its glucuronide conjugate 16 (YM-222714) as an active metabolite after oral administration and it plays a major role in expression of potent anticoagulant activity in plasma. The distinctive, potent activity of inhibitor 14i after oral dosing was explained by this unique pharmacokinetic profile and its favorable membrane permeability. Compound 14i is currently undergoing clinical development for prevention and treatment of thromboembolic diseases.